- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01590901
Pharmacokinetics and Safety Study of Probucol by Multiple Administration in Healthy Male Subjects
The Pharmacokinetics and Safety Study of Probucol by Multiple Administration in Healthy Male Subjects
Study Overview
Detailed Description
This is a single dose, single period, multiple administration, open-labeled trial in one investigation center.
The screening examination will be completed from Day -14 to Day -2 before investigational medicinal product (IMP) administration. The subjects will be hospitalized on Day -1. From Day 1 (the next day), the subjects will receive probucol twice daily (BID). for 14 consecutive days. On Day 18, the subjects can be discharged after the safety evaluation. The follow-up visit will occur on Day 6, 9, 12, 15, 19, 27 (totally 41 days) after the final dosing day.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Chinese.
- Gender: Male.
- Age 20 to 40 years, (at time of informed consent).
- Body mass index [BMI, body weight (kg) / height (m)2] between 19 and 26 kg/m2, inclusive.
- Nonsmokers (or former smokers): Urinary cotinine level satisfying the criteria for a nonsmoker established by the trial site (at time of screening examination).
- Subjects judged by the investigator to be healthy based on the medical history, physical examination, vital signs, 12 lead ECG, the results of serological test (HIV/HCV Ab, HBsAg and Syphilis Ab) and clinical laboratory tests, etc.
Exclusion Criteria:
- Subjects with hypersensitivity or a history of hypersensitivity to any drug (any prescription or over-the-counter [OTC] drug)
Subjects who meet any of the following lipid criteria in the fasting state (at time of screening examination)
- LDL-C: ≥ 140 mg/dL
- TC: ≥ 220 mg/dL
- HDL-C: < 40 mg/dL
TG: ≥ 150 mg/dL
- LDL-C value will be directly measured or calculated by the Friedewald formula. Friedewald Formula: LDL-C = TC - HDL-C - TG/5 (When TG value is less than 400 mg/dL) LDL-C value will be directly measured when TG value is 400 mg/dL or greater.
- Subjects with electrocardiogram (ECG) results showing AV block or with both QTc and QRS width outside the standard values of the ECG laboratory (at time of screening examination)
- Subjects with alcohol or drug dependence or a history of drug abuse
- Subjects who have a positive result in an infectious disease test or urine drug test (at time of screening examination)
Use of any of the following within the specified period prior to scheduled investigational medicinal product (IMP) administration
- All other prescription and OTC drugs (within 2 weeks prior to scheduled IMP administration)
- Alcohol and caffeine-containing products (within 1 week prior to scheduled IMP administration)
- Use of any other investigational drug within 16 weeks prior to scheduled IMP administration in the present trial
- Plasmapheresis or plateletpheresis within 2 weeks or whole blood collection (blood donation, etc) cumulatively exceeding 200 mL within 4 weeks, 400 mL within 12 weeks, or 1200 mL within 1 year prior to scheduled IMP administration
- Subjects whose body weight is less than 50 kg (at time of screening examination)
- Subjects who are scheduled for examination or treatment at any other hospital or clinic during the trial period
- Subjects otherwise judged by the investigator or sub investigator to be inappropriate for inclusion in the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: probucol in healthy male subjects
multiple oral doses of probucol in single group of healthy male subjects
|
250mg (1 tablet) bid.
p.o for 14 consecutive days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic parameters
Time Frame: Day 1, 3, 5, 7, 9, 11, 12, 13, 14
|
Pharmacokinetic parameters: Day 1 (Plasma PK parameters over the 24h dosing period): Cmax, Cmax1, Cmax2, tmax1, tmax2, AUC (0-10)h, AUC (10-24)h, AUC24h, C24h; Day3,5,7,9,11,12,13:C24h; Day 14: Cmax, Cmax1, Cmax2, tmax1, tmax2, AUC (0-10)h, AUC (10-24)h, AUC24h, C24h, Clast, tlast, t1/2,z,Lambdaz, DF, CL/F, Vz/F, AUC_%Extrap; Accumulation evaluation parameters: Rpred, R14,ac(AUC24h), R14,ac(Cmax), R14,ac(C24h), R14,ac[AUC(0-10h)], R14,ac[AUC(10-24h)], R14,ac(Cmax1), R14,ac(Cmax2). |
Day 1, 3, 5, 7, 9, 11, 12, 13, 14
|
Collaborators and Investigators
Investigators
- Principal Investigator: Pei Hu, PHD, Clinical Pharmacology Research Center of Peking Union Medical College Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 009-11-803-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Probucol
-
Korea Otsuka Pharmaceutical Co., Ltd.CompletedDiabetic NephropathyKorea, Republic of
-
Otsuka Beijing Research InstituteCompleted
-
First Affiliated Hospital of Wannan Medical CollegeBeijing Tiantan HospitalNot yet recruiting
-
Korea Otsuka Pharmaceutical Co., Ltd.Completed
-
Yonsei UniversityKorea Otsuka Pharmaceutical Co., Ltd.Completed
-
Yokohama City University Medical CenterCompleted
-
Otsuka Beijing Research InstituteCompletedAtherosclerosis Cerebral InfarctionChina
-
Korea Otsuka Pharmaceutical Co., Ltd.CompletedPeripheral Artery DiseaseKorea, Republic of
-
Deutsches Herzzentrum MuenchenCompletedCoronary Heart DiseaseGermany
-
Otsuka Beijing Research InstituteCompleted